Completed PHASE3 INTERVENTIONAL NCT00233597

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients

A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Hemodialysis Patients Who Are Receiving Supplemental EPO Therapy

Sponsor: AMAG Pharmaceuticals, Inc.

Conditions Anemia

Interventions ferumoxytol or oral iron

Updated 7 times since 2017 Last updated: Apr 1, 2022 Started: Aug 31, 2004 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00233597, this PHASE3 trial focuses on Anemia and remains completed. Sponsored by AMAG Pharmaceuticals, Inc., it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — May 2022 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AMAG Pharmaceuticals, Inc.

Data source: AMAG Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Alexandria, United States , Appleton, United States , Augusta, United States , Austin, United States , Baton Rouge, United States , Bethesda, United States , Boston, United States , Brooklyn, United States , Chapel Hill, United States and 35 more locations